You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
衆生藥業(002317.SZ):RAY1225注射液的臨牀試驗進度、審評和審批的結果等具有一定的不確定性

格隆匯6月10日丨衆生藥業(002317.SZ)公佈,在研產品RAY1225注射液屬於長效GLP-1類藥物,具有GLP-1受體和GIP受體雙重激動活性,臨牀上擬用於2型糖尿病及超重/肥胖等患者的治療。目前,RAY1225注射液治療超重/肥胖患者的III期臨牀試驗以及用於2型糖尿病患者的兩項III期臨牀試驗已獲得臨牀試驗倫理批件。RAY1225注射液的臨牀試驗進度、審評和審批的結果以及未來產品市場競爭格局都具有一定的不確定性。藥品能否獲批上市以及獲批上市的時間、上市後的生產和銷售情況存在不確定性。

用於治療甲型流感的小分子創新藥昂拉地韋片(商品名:安睿威®)已獲得國家藥品監督管理局批準上市。由於醫藥產品的行業特點,藥品獲批後的銷售將受到市場、政策、環境變化等不確定因素影響,存在銷售不達預期的風險。受相關疾病的預防性疫苗的普及、治療藥物的陸續獲批、後續產品市場推廣等多種因素影響,未來昂拉地韋片的商業化和銷售情況存在不確定性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account